Cargando…

Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores

BACKGROUND & AIMS: Currently available non-invasive tests, including fibrosis-4 index (FIB-4) and liver stiffness measurement (LSM by VCTE), are highly effective at excluding advanced fibrosis (AF) (F ≥3) or cirrhosis in people with non-alcoholic fatty liver disease (NAFLD), but only have modera...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sanyal, Arun J., Foucquier, Julie, Younossi, Zobair M., Harrison, Stephen A., Newsome, Philip N., Chan, Wah-Kheong, Yilmaz, Yusuf, De Ledinghen, Victor, Costentin, Charlotte, Zheng, Ming-Hua, Wong, Vincent Wai-Sun, Elkhashab, Magdy, Huss, Ryan S., Myers, Robert P., Roux, Marine, Labourdette, Aymeric, Destro, Marie, Fournier-Poizat, Céline, Miette, Véronique, Sandrin, Laurent, Boursier, Jérôme
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10170177/ https://www.ncbi.nlm.nih.gov/pubmed/36375686 http://dx.doi.org/10.1016/j.jhep.2022.10.034

Ejemplares similares

FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study
por: Newsome, Philip N, et al.
Publicado: (2020)

Liver Stiffness Measurement With FibroScan: Use the Right Probe in the Right Conditions!
por: Berger, Arthur, et al.
Publicado: (2019)

Direct comparison of the FibroScan XL and M probes for assessment of liver fibrosis in obese and nonobese patients
por: Durango, Esteban, et al.
Publicado: (2013)

Diagnostic Accuracy of FibroScan and Factors Affecting Measurements
por: Oeda, Satoshi, et al.
Publicado: (2020)

Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis
por: Friedrich-Rust, Mireen, et al.
Publicado: (2010)

Attenuation parameter and liver stiffness measurement using FibroTouch vs Fibroscan in patients with chronic liver disease
por: Ng, Ying Zhuang, et al.
Publicado: (2021)

The discriminatory ability of FibroScan liver stiffness measurement, controlled attenuation parameter, and FibroScan–aspartate aminotransferase to predict severity of liver disease in children
por: Chaidez, Alexander, et al.
Publicado: (2022)

Prospective Comparison of Transient Elastography Using Two Different Devices: Performance of FibroScan and FibroTouch
por: Serra, Joao Tiago, et al.
Publicado: (2020)

The clinical utility of FibroScan(®) as a noninvasive diagnostic test for liver disease
por: Wilder, Julius, et al.
Publicado: (2014)

Points to Be Considered When Applying FibroScan S Probe in Children With Biliary Atresia
por: Kim, Seung, et al.
Publicado: (2014)

A prospective comparative assessment of the accuracy of the FibroScan in evaluating liver steatosis
por: Jun, Baek Gyu, et al.
Publicado: (2017)

Estimation of Liver Fat by FibroScan in Patients With Nonalcoholic Fatty Liver Disease
por: Shrestha, Rupesh, et al.
Publicado: (2021)

The role of FibroScan in the era of metabolic (dysfunction)-associated fatty liver disease
por: Yilmaz, Yusuf, et al.
Publicado: (2023)

Serum uric acid to creatinine ratio is associated with higher prevalence of NAFLD detected by FibroScan in the United States
por: Wang, Rusha, et al.
Publicado: (2022)

Safety Profile of Liver FibroScan in Patients with Cardiac Pacemakers or Implantable Cardioverter-Defibrillators
por: Chan, Yin, et al.
Publicado: (2017)

FIB-4 is closer to FibroScan screen results to detecting advanced liver fibrosis and maybe facilitates NAFLD warning
por: Ding, Yuping, et al.
Publicado: (2023)

Correlates of hepatic stiffness by FibroScan(©) in a multicentric Italian cohort of HIV-infected patients
por: Tarquini, P, et al.
Publicado: (2010)

Use of aspartate aminotransferase to platelet ratio to reduce the need for FibroScan in the evaluation of liver fibrosis
por: Wong, Stephanie, et al.
Publicado: (2017)

FibroScan Detection of Fatty Liver/Liver Fibrosis in 2266 Cases of Chronic Hepatitis B
por: He, Tingshan, et al.
Publicado: (2020)

Liver Biopsy and FibroScan to Detect Early Histopathological Changes in Chronic HBV Patients Not Candidate for Treatment
por: Maklad, Sahar, et al.
Publicado: (2014)

Validation of Novel Fibrosis Index (NFI) for assessment of liver fibrosis: comparison with transient elastography (FibroScan)
por: Hussain, Azhar, et al.
Publicado: (2019)

The association of weight gain with nonalcoholic fatty liver disease and fibrosis detected by FibroScan in the United States
por: Wijarnpreecha, Karn, et al.
Publicado: (2022)

Practical diagnosis of cirrhosis in non-alcoholic fatty liver disease using currently available non-invasive fibrosis tests
por: Boursier, Jérôme, et al.
Publicado: (2023)

Diagnostic accuracy of transient elastography (FibroScan) in detection of esophageal varices in patients with cirrhosis: A meta-analysis
por: Pu, Ke, et al.
Publicado: (2017)

Validation of Controlled Attenuation Parameter Measured by FibroScan as a Novel Surrogate Marker for the Evaluation of Metabolic Derangement
por: Huang, Zhimin, et al.
Publicado: (2022)

Clinical relevance of lipid panel and aminotransferases in the context of hepatic steatosis and fibrosis as measured by transient elastography (FibroScan®)
por: Chi-Cervera, Luis Alberto, et al.
Publicado: (2021)

Effect of FibroScan test in antiviral therapy for HBV-infected patients with ALT <2 upper limit of normal
por: Han, Xian-Zhi, et al.
Publicado: (2020)

Utility of FibroScan-based scoring systems to narrow the risk group of nonalcoholic fatty liver disease with comorbidities
por: Miura, Kouichi, et al.
Publicado: (2022)

2209. Discordance Between FibroSure and FibroScan Results in Hepatitis C and Human Immunodeficiency Virus Co-infected Patients Prior to Treatment for Hepatitis C Virus Infection
por: Tiyouh, Melissa, et al.
Publicado: (2018)

Feasibility study and reference values of FibroScan 502 with M probe in healthy preschool children aged 5 years
por: Zeng, Jing, et al.
Publicado: (2019)

Accuracy of FibroScan in analysis of liver fibrosis in patients with concomitant chronic Hepatitis B and nonalcoholic fatty liver disease
por: Li, Qiang, et al.
Publicado: (2020)

Performance of liver stiffness measurements obtained with FibroScan is affected by glucose metabolism in patients with nonalcoholic fatty liver disease
por: Yang, Xinyu, et al.
Publicado: (2021)

Comparing the controlled attenuation parameter using FibroScan and attenuation imaging with ultrasound as a novel measurement for liver steatosis
por: Hsu, Po-Ke, et al.
Publicado: (2021)

The FibroScan-aspartate aminotransferase score can stratify the disease severity in a Japanese cohort with fatty liver diseases
por: Fujii, Hideki, et al.
Publicado: (2021)

Correlation between Cumulative Methotrexate Dose, Metabolic Syndrome and Hepatic Fibrosis Detected by FibroScan in Rheumatoid Arthritis Patients
por: Lertnawapan, Ratchaya, et al.
Publicado: (2023)

Discordance between Liver Biopsy and FibroScan® in Assessing Liver Fibrosis in Chronic Hepatitis B: Risk Factors and Influence of Necroinflammation
por: Kim, Seung Up, et al.
Publicado: (2012)

Prospective Validation of ELF Test in Comparison with Fibroscan and FibroTest to Predict Liver Fibrosis in Asian Subjects with Chronic Hepatitis B
por: Kim, Beom Kyung, et al.
Publicado: (2012)

Effect of 48‐week pemafibrate on non‐alcoholic fatty liver disease with hypertriglyceridemia, as evaluated by the FibroScan‐aspartate aminotransferase score
por: Hatanaka, Takeshi, et al.
Publicado: (2021)

FibroScan-AST Score Predicts 30-Day Mortality or Need for Mechanical Ventilation among Patients Hospitalized with COVID-19
por: Zelenika, Marko, et al.
Publicado: (2021)

Retraction: Comparing the controlled attenuation parameter using FibroScan and attenuation imaging with ultrasound as a novel measurement for liver steatosis
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_v3tt8nlosqahd4pb21vk2orv5s